Core Viewpoint - The company reported a significant decline in revenue and net profit for the third quarter of 2023, indicating potential challenges in its business operations [1] Financial Performance - Revenue for the first three quarters of 2023 was approximately 209 million yuan, a year-on-year decrease of 28.6% [1] - Net profit attributable to shareholders was about 33.11 million yuan, reflecting a year-on-year decline of 57.44% [1] - Basic earnings per share were 0.5 yuan, down 57.26% compared to the previous year [1] Business Strategy - The company is actively monitoring opportunities in the upstream and downstream industrial layout of its main business [1] - The company emphasizes strict compliance with relevant laws and regulations, asserting that there are no undisclosed significant matters [1] - The company commits to timely information disclosure regarding any significant matters that may arise in the future [1]
万邦医药：前三季度营收同比减少28.6%至2.09亿元，公司一直关注主营业务上下游的产业布局机会